SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Over 30 million psychedelic users in the United States
2 references·10 citing·42 second hop
Over 30 million psychedelic users in the United States (2013)Over 30 million psychedelic users in the …Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior (2007)Hallucinogens Recruit Specifi…Hallucinogens (2004)HallucinogensHOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer (2023)HOPE: A Pilot Study of Psiloc…The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation (2022)The effects of psilocybin on …Use of psilocybin (“mushrooms”) among US adults: 2015–2018 (2021)Use of psilocybin (“mushrooms…Associations between lifetime classic psychedelic use and markers of physical health (2021)Associations between lifetime…Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers (2021)Adults who microdose psychede…Trends in LSD use among US adults: 2015–2018 (2020)Trends in LSD use among US ad…Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants (2020)Pharmacokinetics and Pharmaco…Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects (2019)Pharmacokinetics and subjecti…Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD) (2018)Dark Classics in Chemical Neu…Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy (2017)Psychedelic drug use in healt…Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action (1998)Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex (2003)Human hallucinogen research: guidelines for safety (2008)The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs (2014)Psychedelics (2016)Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD) (2019)Psychedelics and Psychedelic-Assisted Psychotherapy (2020)Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants (2023)Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases (2014)Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution (2016)Neural correlates of the LSD experience revealed by multimodal neuroimaging (2016)Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin (2021)Safety pharmacology of acute LSD administration in healthy subjects (2021)Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population (2015)Modern Clinical Research on LSD (2017)Psychedelic perceptions: mental health service user attitudes to psilocybin therapy (2021)Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP (2022)Case analysis of long-term negative psychological responses to psychedelics (2023)Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials (2012)Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects (2014)Short screening scales to monitor population prevalences and trends in non-specific psychological distress (2002)Screening for serious mental illness in the general population with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative (2010)Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (2016)Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample (2022)Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics (2023)Pattern breaking: a complex systems approach to psychedelic medicine (2023)The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories (1995)A systematic study of microdosing psychedelics (2019)Classical psychedelics for the treatment of depression and anxiety: A systematic review (2019)Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls (2022)Development and validation of brief measures of positive and negative affect: The PANAS scales. (1988)Development and validation of brief measures of positive and negative affect: The PANAS scales. (1988)The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. (1998)A unified model of ketamine’s dissociative and psychedelic properties (2022)Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report (2022)Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies (2023)One-Month Prevalence of Mental Disorders in the United States (1988)Drug-activation of brain reward pathways (1998)Psychedelics Promote Structural and Functional Neural Plasticity (2018)A RATING SCALE FOR DEPRESSION (1960)The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults (2011)Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016)
this work references cited by second hop

References

  • 2004Hallucinogens1,259 cited
  • 2007Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior945 cited

Cited by

  • 2020Trends in LSD use among US adults: 2015–2018111 cited
  • 2022The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation105 cited
  • 2018Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)91 cited
  • 2021Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers79 cited
  • 2021Associations between lifetime classic psychedelic use and markers of physical health74 cited
  • 2019Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects73 cited
  • 2023HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer70 cited
  • 2020Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants65 cited
  • 2021Use of psilocybin (“mushrooms”) among US adults: 2015–201864 cited
  • 2017Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy57 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work